Edwards Lifesciences Corporation Earnings Recaps
Q2 2026
Jul 25, 2026
Edwards Lifesciences shares declined 2.1% following Q2 earnings, reflecting cautious investor response despite solid sales growth, as the market weighed lingering uncertainties regarding margin expansion and long-term growth visibility.
Key takeaways
- Reported 12.5% underlying sales growth in Q2, driven by broad strength across TAVR, TMTT, Surgical segments, and geographic regions.
- Management raised full-year 2026 sales growth guidance to 10–11% for the company, with continued focus on innovation and portfolio expansion.
- Earnings guidance was reaffirmed, indicating stable margin expectations despite investment in new therapies and technology development.
- Multiple upcoming clinical and regulatory milestones, including updated U.S. TAVR coverage decisions and new indications for PASCAL, present potential catalysts but also introduce execution risk.
- Market reaction suggests investor concerns remain around margin compression and the pacing of adoption in key therapy areas, tempering enthusiasm despite positive operational developments.
Q3 2025
Oct 31, 2025
Edwards Lifesciences delivered strong Q3 2025 results with 12.6% sales growth, driven by a comprehensive portfolio in structural heart therapies, prompting an upward revision of full-year guidance for sales and EPS.
Key takeaways
- Q3 revenues reached $1.55 billion, exceeding expectations and reinforcing the company's growth strategy.
- Full-year sales growth guidance revised to the upper end of 9-10% range, with EPS guidance raised to $2.56–$2.62.
- Strong performance from innovative TAVR therapies, particularly SAPIEN, enhances long-term adoption and market competitiveness.
- Positive clinical data presented at TCT further supports the efficacy and durability of the TAVR products and positions Edwards for sustained growth in the TMTT market, projected to reach $2 billion by 2030.
- The company’s diverse portfolio now addresses multiple valve disease areas, ensuring comprehensive treatment options for patients and solidifying its leadership in the field.